Eton Pharmaceuticals, Inc. (NASDAQ: ETON) Stock Competitors & Peer Comparison
See ETON's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ETON and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ETON | $68.40 | +1.27% | 2B | 180.00 | $0.38 | N/A |
| TAK | $20.84 | -0.43% | 65.3B | 14.99 | $1.39 | +3.39% |
| TEVA | $43.24 | +1.98% | 50.4B | 14.75 | $2.93 | N/A |
| HLN | $9.10 | +0.44% | 40.3B | 18.59 | $0.49 | +2.17% |
| ZTS | $82.57 | +0.13% | 33.5B | 12.55 | $6.58 | +2.58% |
| VTRS | $21.06 | +1.01% | 24.1B | 8.36 | $2.52 | +2.29% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| ELAN | $26.48 | -1.05% | 13.2B | 24.98 | $1.06 | N/A |
| RDY | $14.84 | -0.13% | 12.4B | 31.57 | $0.47 | +0.56% |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
ETON vs TAK Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, TAK has a market cap of 65.3B. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while TAK trades at $20.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas TAK's P/E ratio is 14.99. In terms of profitability, ETON's ROE is +1.05%, compared to TAK's ROE of +0.05%. Regarding short-term risk, ETON is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for ETON.Check TAK's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
ETON vs TEVA Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, TEVA has a market cap of 50.4B. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while TEVA trades at $43.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas TEVA's P/E ratio is 14.75. In terms of profitability, ETON's ROE is +1.05%, compared to TEVA's ROE of +0.06%. Regarding short-term risk, ETON is more volatile compared to TEVA. This indicates higher risk in terms of short-term price fluctuations for ETON.Check TEVA's competition here
Haleon plc (NYSE: HLN)
ETON vs HLN Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, HLN has a market cap of 40.3B. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while HLN trades at $9.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas HLN's P/E ratio is 18.59. In terms of profitability, ETON's ROE is +1.05%, compared to HLN's ROE of +0.10%. Regarding short-term risk, ETON is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for ETON.Check HLN's competition here
Zoetis Inc. (NYSE: ZTS)
ETON vs ZTS Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, ZTS has a market cap of 33.5B. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while ZTS trades at $82.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas ZTS's P/E ratio is 12.55. In terms of profitability, ETON's ROE is +1.05%, compared to ZTS's ROE of +0.76%. Regarding short-term risk, ETON is more volatile compared to ZTS. This indicates higher risk in terms of short-term price fluctuations for ETON.Check ZTS's competition here
Viatris Inc. (NASDAQ: VTRS)
ETON vs VTRS Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, VTRS has a market cap of 24.1B. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while VTRS trades at $21.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas VTRS's P/E ratio is 8.36. In terms of profitability, ETON's ROE is +1.05%, compared to VTRS's ROE of -0.04%. Regarding short-term risk, ETON is more volatile compared to VTRS. This indicates higher risk in terms of short-term price fluctuations for ETON.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
ETON vs ITCI Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas ITCI's P/E ratio is -180.64. In terms of profitability, ETON's ROE is +1.05%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, ETON is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for ETON.Check ITCI's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
ETON vs ELAN Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, ELAN has a market cap of 13.2B. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while ELAN trades at $26.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas ELAN's P/E ratio is 24.98. In terms of profitability, ETON's ROE is +1.05%, compared to ELAN's ROE of -0.02%. Regarding short-term risk, ETON is more volatile compared to ELAN. This indicates higher risk in terms of short-term price fluctuations for ETON.Check ELAN's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
ETON vs RDY Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, RDY has a market cap of 12.4B. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while RDY trades at $14.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas RDY's P/E ratio is 31.57. In terms of profitability, ETON's ROE is +1.05%, compared to RDY's ROE of +0.07%. Regarding short-term risk, ETON is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for ETON.Check RDY's competition here
Catalent, Inc. (NYSE: CTLT)
ETON vs CTLT Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas CTLT's P/E ratio is -27.84. In terms of profitability, ETON's ROE is +1.05%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, ETON is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for ETON.Check CTLT's competition here
Alkermes plc (NASDAQ: ALKS)
ETON vs ALKS Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, ALKS has a market cap of 8B. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while ALKS trades at $47.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas ALKS's P/E ratio is 50.41. In terms of profitability, ETON's ROE is +1.05%, compared to ALKS's ROE of -0.00%. Regarding short-term risk, ETON is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for ETON.Check ALKS's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
ETON vs AMRX Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, AMRX has a market cap of 7.6B. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while AMRX trades at $21.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas AMRX's P/E ratio is 24.12. In terms of profitability, ETON's ROE is +1.05%, compared to AMRX's ROE of +1.32%. Regarding short-term risk, ETON is more volatile compared to AMRX. This indicates higher risk in terms of short-term price fluctuations for ETON.Check AMRX's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
ETON vs LNTH Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while LNTH trades at $101.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas LNTH's P/E ratio is 17.08. In terms of profitability, ETON's ROE is +1.05%, compared to LNTH's ROE of +0.22%. Regarding short-term risk, ETON is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for ETON.Check LNTH's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
ETON vs INDV Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, INDV has a market cap of 4.5B. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while INDV trades at $36.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas INDV's P/E ratio is 9.94. In terms of profitability, ETON's ROE is +1.05%, compared to INDV's ROE of -3.53%. Regarding short-term risk, ETON is more volatile compared to INDV. This indicates higher risk in terms of short-term price fluctuations for ETON.Check INDV's competition here
Bausch Health Companies Inc. (NYSE: BHC)
ETON vs BHC Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, BHC has a market cap of 3.1B. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while BHC trades at $8.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas BHC's P/E ratio is 2.13. In terms of profitability, ETON's ROE is +1.05%, compared to BHC's ROE of +0.59%. Regarding short-term risk, ETON is more volatile compared to BHC. This indicates higher risk in terms of short-term price fluctuations for ETON.Check BHC's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
ETON vs RGC Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, RGC has a market cap of 2.7B. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while RGC trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas RGC's P/E ratio is -541.00. In terms of profitability, ETON's ROE is +1.05%, compared to RGC's ROE of -1.61%. Regarding short-term risk, ETON is more volatile compared to RGC. This indicates higher risk in terms of short-term price fluctuations for ETON.Check RGC's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
ETON vs HCM Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, HCM has a market cap of 2.6B. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while HCM trades at $15.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas HCM's P/E ratio is 145.84. In terms of profitability, ETON's ROE is +1.05%, compared to HCM's ROE of +0.01%. Regarding short-term risk, ETON is more volatile compared to HCM. This indicates higher risk in terms of short-term price fluctuations for ETON.Check HCM's competition here
Perrigo Company plc (NYSE: PRGO)
ETON vs PRGO Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, PRGO has a market cap of 2.3B. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while PRGO trades at $16.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas PRGO's P/E ratio is 6.62. In terms of profitability, ETON's ROE is +1.05%, compared to PRGO's ROE of -0.68%. Regarding short-term risk, ETON is more volatile compared to PRGO. This indicates higher risk in terms of short-term price fluctuations for ETON.Check PRGO's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
ETON vs DCPH Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas DCPH's P/E ratio is -11.58. In terms of profitability, ETON's ROE is +1.05%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, ETON is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for ETON.Check DCPH's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
ETON vs AVDL Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, ETON's ROE is +1.05%, compared to AVDL's ROE of +0.10%. Regarding short-term risk, ETON is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for ETON.Check AVDL's competition here
Trulieve Cannabis Corp. (NYSE: TRLV)
ETON vs TRLV Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, TRLV has a market cap of 1.9B. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while TRLV trades at $11.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas TRLV's P/E ratio is -4.57. In terms of profitability, ETON's ROE is +1.05%, compared to TRLV's ROE of -0.46%. Regarding short-term risk, ETON is more volatile compared to TRLV. This indicates higher risk in terms of short-term price fluctuations for ETON.Check TRLV's competition here
Embecta Corp. (NASDAQ: EMBCV)
ETON vs EMBCV Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas EMBCV's P/E ratio is N/A. In terms of profitability, ETON's ROE is +1.05%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, ETON is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for ETON.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
ETON vs DVAX Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas DVAX's P/E ratio is -41.89. In terms of profitability, ETON's ROE is +1.05%, compared to DVAX's ROE of +0.09%. Regarding short-term risk, ETON is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for ETON.Check DVAX's competition here
Alvotech (NASDAQ: ALVO)
ETON vs ALVO Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, ALVO has a market cap of 1.8B. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while ALVO trades at $4.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas ALVO's P/E ratio is -8.34. In terms of profitability, ETON's ROE is +1.05%, compared to ALVO's ROE of +0.77%. Regarding short-term risk, ETON is more volatile compared to ALVO. This indicates higher risk in terms of short-term price fluctuations for ETON.Check ALVO's competition here
Supernus, Inc. (NASDAQ: SUPN)
ETON vs SUPN Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, SUPN has a market cap of 1.7B. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while SUPN trades at $29.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas SUPN's P/E ratio is -38.89. In terms of profitability, ETON's ROE is +1.05%, compared to SUPN's ROE of -3.53%. Regarding short-term risk, ETON is more volatile compared to SUPN. This indicates higher risk in terms of short-term price fluctuations for ETON.Check SUPN's competition here
Alvotech (NASDAQ: ALVOW)
ETON vs ALVOW Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, ALVOW has a market cap of 1.7B. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while ALVOW trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas ALVOW's P/E ratio is 26.59. In terms of profitability, ETON's ROE is +1.05%, compared to ALVOW's ROE of +0.77%. Regarding short-term risk, ETON is more volatile compared to ALVOW. This indicates higher risk in terms of short-term price fluctuations for ETON.Check ALVOW's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
ETON vs ANIP Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, ANIP has a market cap of 1.6B. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while ANIP trades at $71.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas ANIP's P/E ratio is 8.65. In terms of profitability, ETON's ROE is +1.05%, compared to ANIP's ROE of +0.20%. Regarding short-term risk, ETON is more volatile compared to ANIP. This indicates higher risk in terms of short-term price fluctuations for ETON.Check ANIP's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
ETON vs TARO Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas TARO's P/E ratio is 30.05. In terms of profitability, ETON's ROE is +1.05%, compared to TARO's ROE of +0.03%. Regarding short-term risk, ETON is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for ETON.Check TARO's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
ETON vs PCRX Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, PCRX has a market cap of 1.5B. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while PCRX trades at $36.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas PCRX's P/E ratio is 14.02. In terms of profitability, ETON's ROE is +1.05%, compared to PCRX's ROE of +0.06%. Regarding short-term risk, ETON is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for ETON.Check PCRX's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
ETON vs PAHC Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, PAHC has a market cap of 1.4B. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while PAHC trades at $35.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas PAHC's P/E ratio is 12.00. In terms of profitability, ETON's ROE is +1.05%, compared to PAHC's ROE of +0.27%. Regarding short-term risk, ETON is more volatile compared to PAHC. This indicates higher risk in terms of short-term price fluctuations for ETON.Check PAHC's competition here
Cronos Group Inc. (NASDAQ: CRON)
ETON vs CRON Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, CRON has a market cap of 1.3B. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while CRON trades at $3.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas CRON's P/E ratio is 17.67. In terms of profitability, ETON's ROE is +1.05%, compared to CRON's ROE of +0.05%. Regarding short-term risk, ETON is more volatile compared to CRON. This indicates higher risk in terms of short-term price fluctuations for ETON.Check CRON's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
ETON vs AMPH Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, AMPH has a market cap of 1.2B. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while AMPH trades at $28.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas AMPH's P/E ratio is 9.76. In terms of profitability, ETON's ROE is +1.05%, compared to AMPH's ROE of +0.13%. Regarding short-term risk, ETON is more volatile compared to AMPH. This indicates higher risk in terms of short-term price fluctuations for ETON.Check AMPH's competition here
Harrow Health, Inc. (NASDAQ: HROW)
ETON vs HROW Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, HROW has a market cap of 1.1B. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while HROW trades at $29.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas HROW's P/E ratio is -29.67. In terms of profitability, ETON's ROE is +1.05%, compared to HROW's ROE of -0.91%. Regarding short-term risk, ETON is more volatile compared to HROW. This indicates higher risk in terms of short-term price fluctuations for ETON.Check HROW's competition here
PetIQ, Inc. (NASDAQ: PETQ)
ETON vs PETQ Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas PETQ's P/E ratio is 83.73. In terms of profitability, ETON's ROE is +1.05%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, ETON is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for ETON.Check PETQ's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
ETON vs IRWD Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, IRWD has a market cap of 806.2M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while IRWD trades at $4.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas IRWD's P/E ratio is 6.24. In terms of profitability, ETON's ROE is +1.05%, compared to IRWD's ROE of -0.93%. Regarding short-term risk, ETON is more volatile compared to IRWD. This indicates higher risk in terms of short-term price fluctuations for ETON.Check IRWD's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
ETON vs COLL Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, COLL has a market cap of 771M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while COLL trades at $24.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas COLL's P/E ratio is 3.11. In terms of profitability, ETON's ROE is +1.05%, compared to COLL's ROE of +0.12%. Regarding short-term risk, ETON is more volatile compared to COLL. This indicates higher risk in terms of short-term price fluctuations for ETON.Check COLL's competition here
Evotec SE (NASDAQ: EVO)
ETON vs EVO Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, EVO has a market cap of 600.3M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while EVO trades at $1.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas EVO's P/E ratio is -2.39. In terms of profitability, ETON's ROE is +1.05%, compared to EVO's ROE of -0.26%. Regarding short-term risk, ETON is more volatile compared to EVO. This indicates higher risk in terms of short-term price fluctuations for ETON.Check EVO's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
ETON vs BDSI Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas BDSI's P/E ratio is 6.82. In terms of profitability, ETON's ROE is +1.05%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, ETON is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for ETON.Check BDSI's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
ETON vs TKNO Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, TKNO has a market cap of 541M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while TKNO trades at $8.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas TKNO's P/E ratio is -27.81. In terms of profitability, ETON's ROE is +1.05%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, ETON is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for ETON.Check TKNO's competition here
Evolus, Inc. (NASDAQ: EOLS)
ETON vs EOLS Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, EOLS has a market cap of 491.1M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while EOLS trades at $7.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas EOLS's P/E ratio is -23.50. In terms of profitability, ETON's ROE is +1.05%, compared to EOLS's ROE of +1.03%. Regarding short-term risk, ETON is more volatile compared to EOLS. This indicates higher risk in terms of short-term price fluctuations for ETON.Check EOLS's competition here
Kamada Ltd. (NASDAQ: KMDA)
ETON vs KMDA Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, KMDA has a market cap of 469.1M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while KMDA trades at $8.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas KMDA's P/E ratio is 21.39. In terms of profitability, ETON's ROE is +1.05%, compared to KMDA's ROE of +0.09%. Regarding short-term risk, ETON is more volatile compared to KMDA. This indicates higher risk in terms of short-term price fluctuations for ETON.Check KMDA's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
ETON vs AQST Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, AQST has a market cap of 450M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while AQST trades at $3.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas AQST's P/E ratio is -5.51. In terms of profitability, ETON's ROE is +1.05%, compared to AQST's ROE of +2.55%. Regarding short-term risk, ETON is more volatile compared to AQST. This indicates higher risk in terms of short-term price fluctuations for ETON.Check AQST's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
ETON vs ACB Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, ACB has a market cap of 332M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while ACB trades at $5.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas ACB's P/E ratio is -3.65. In terms of profitability, ETON's ROE is +1.05%, compared to ACB's ROE of -0.15%. Regarding short-term risk, ETON is more volatile compared to ACB. This indicates higher risk in terms of short-term price fluctuations for ETON.Check ACB's competition here
Emergent BioSolutions Inc. (NYSE: EBS)
ETON vs EBS Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, EBS has a market cap of 310.5M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while EBS trades at $6.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas EBS's P/E ratio is 4.19. In terms of profitability, ETON's ROE is +1.05%, compared to EBS's ROE of -0.61%. Regarding short-term risk, ETON is more volatile compared to EBS. This indicates higher risk in terms of short-term price fluctuations for ETON.Check EBS's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
ETON vs ALIM Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas ALIM's P/E ratio is 5.28. In terms of profitability, ETON's ROE is +1.05%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, ETON is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for ETON.Check ALIM's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
ETON vs TLRY Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, TLRY has a market cap of 291.9M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while TLRY trades at $2.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas TLRY's P/E ratio is -1.86. In terms of profitability, ETON's ROE is +1.05%, compared to TLRY's ROE of -0.10%. Regarding short-term risk, ETON is more volatile compared to TLRY. This indicates higher risk in terms of short-term price fluctuations for ETON.Check TLRY's competition here
Landec Corporation (NASDAQ: LNDC)
ETON vs LNDC Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas LNDC's P/E ratio is -4.04. In terms of profitability, ETON's ROE is +1.05%, compared to LNDC's ROE of +5.75%. Regarding short-term risk, ETON is more volatile compared to LNDC. This indicates higher risk in terms of short-term price fluctuations for ETON.Check LNDC's competition here
Canopy Growth Corporation (NASDAQ: CGC)
ETON vs CGC Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, CGC has a market cap of 256.1M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while CGC trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas CGC's P/E ratio is -1.35. In terms of profitability, ETON's ROE is +1.05%, compared to CGC's ROE of -0.39%. Regarding short-term risk, ETON is more volatile compared to CGC. This indicates higher risk in terms of short-term price fluctuations for ETON.Check CGC's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
ETON vs LFCR Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, LFCR has a market cap of 242.6M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while LFCR trades at $6.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas LFCR's P/E ratio is -5.04. In terms of profitability, ETON's ROE is +1.05%, compared to LFCR's ROE of +3.82%. Regarding short-term risk, ETON is more volatile compared to LFCR. This indicates higher risk in terms of short-term price fluctuations for ETON.Check LFCR's competition here
Shineco, Inc. (NASDAQ: TYHT)
ETON vs TYHT Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas TYHT's P/E ratio is -1.61. In terms of profitability, ETON's ROE is +1.05%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, ETON is more volatile compared to TYHT. This indicates higher risk in terms of short-term price fluctuations for ETON.Check TYHT's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
ETON vs SIGA Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, SIGA has a market cap of 225.6M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while SIGA trades at $3.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas SIGA's P/E ratio is 11.63. In terms of profitability, ETON's ROE is +1.05%, compared to SIGA's ROE of +0.00%. Regarding short-term risk, ETON is more volatile compared to SIGA. This indicates higher risk in terms of short-term price fluctuations for ETON.Check SIGA's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
ETON vs REPH Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas REPH's P/E ratio is -8.04. In terms of profitability, ETON's ROE is +1.05%, compared to REPH's ROE of -0.22%. Regarding short-term risk, ETON is more volatile compared to REPH. This indicates higher risk in terms of short-term price fluctuations for ETON.Check REPH's competition here
Glass House Brands Inc (NYSE: GLAS)
ETON vs GLAS Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, GLAS has a market cap of 166.8M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while GLAS trades at $1.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas GLAS's P/E ratio is -3.39. In terms of profitability, ETON's ROE is +1.05%, compared to GLAS's ROE of -0.51%. Regarding short-term risk, ETON is more volatile compared to GLAS. This indicates higher risk in terms of short-term price fluctuations for ETON.Check GLAS's competition here
Theratechnologies Inc. (NASDAQ: THTX)
ETON vs THTX Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas THTX's P/E ratio is -28.83. In terms of profitability, ETON's ROE is +1.05%, compared to THTX's ROE of +0.36%. Regarding short-term risk, ETON is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for ETON.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
ETON vs ASRT Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas ASRT's P/E ratio is -7.10. In terms of profitability, ETON's ROE is +1.05%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, ETON is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for ETON.Check ASRT's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
ETON vs ORGO Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, ORGO has a market cap of 136.3M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while ORGO trades at $1.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas ORGO's P/E ratio is 35.00. In terms of profitability, ETON's ROE is +1.05%, compared to ORGO's ROE of -0.46%. Regarding short-term risk, ETON is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for ETON.Check ORGO's competition here
Journey Medical Corporation (NASDAQ: DERM)
ETON vs DERM Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, DERM has a market cap of 125.3M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while DERM trades at $4.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas DERM's P/E ratio is -20.18. In terms of profitability, ETON's ROE is +1.05%, compared to DERM's ROE of -0.20%. Regarding short-term risk, ETON is more volatile compared to DERM. This indicates higher risk in terms of short-term price fluctuations for ETON.Check DERM's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
ETON vs CRDL Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, CRDL has a market cap of 121.9M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while CRDL trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas CRDL's P/E ratio is -4.02. In terms of profitability, ETON's ROE is +1.05%, compared to CRDL's ROE of -1.94%. Regarding short-term risk, ETON is more volatile compared to CRDL. This indicates higher risk in terms of short-term price fluctuations for ETON.Check CRDL's competition here
Organigram Global Inc. (NASDAQ: OGI)
ETON vs OGI Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, OGI has a market cap of 120.4M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while OGI trades at $0.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas OGI's P/E ratio is 1.92. In terms of profitability, ETON's ROE is +1.05%, compared to OGI's ROE of +0.21%. Regarding short-term risk, ETON is more volatile compared to OGI. This indicates higher risk in terms of short-term price fluctuations for ETON.Check OGI's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
ETON vs SCTL Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas SCTL's P/E ratio is -7.86. In terms of profitability, ETON's ROE is +1.05%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, ETON is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for ETON.Check SCTL's competition here
BGM Group Ltd. (NASDAQ: BGM)
ETON vs BGM Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, BGM has a market cap of 110.4M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while BGM trades at $8.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas BGM's P/E ratio is -1.81. In terms of profitability, ETON's ROE is +1.05%, compared to BGM's ROE of -0.05%. Regarding short-term risk, ETON is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for ETON.Check BGM's competition here
Procaps Group S.A. (NASDAQ: PROC)
ETON vs PROC Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas PROC's P/E ratio is 1.53. In terms of profitability, ETON's ROE is +1.05%, compared to PROC's ROE of -2.22%. Regarding short-term risk, ETON is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for ETON.Check PROC's competition here
OptiNose, Inc. (NASDAQ: OPTN)
ETON vs OPTN Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas OPTN's P/E ratio is -4.42. In terms of profitability, ETON's ROE is +1.05%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, ETON is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for ETON.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
ETON vs ZOM Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas ZOM's P/E ratio is -1.62. In terms of profitability, ETON's ROE is +1.05%, compared to ZOM's ROE of -0.14%. Regarding short-term risk, ETON is more volatile compared to ZOM. This indicates higher risk in terms of short-term price fluctuations for ETON.Check ZOM's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
ETON vs CPIX Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, CPIX has a market cap of 91.7M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while CPIX trades at $6.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas CPIX's P/E ratio is -15.30. In terms of profitability, ETON's ROE is +1.05%, compared to CPIX's ROE of +2.03%. Regarding short-term risk, ETON is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for ETON.Check CPIX's competition here
Upexi, Inc. (NASDAQ: GRVI)
ETON vs GRVI Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas GRVI's P/E ratio is 26.05. In terms of profitability, ETON's ROE is +1.05%, compared to GRVI's ROE of +114.74%. Regarding short-term risk, ETON is more volatile compared to GRVI. This indicates higher risk in terms of short-term price fluctuations for ETON.Check GRVI's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
ETON vs ZYBT Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, ZYBT has a market cap of 71.6M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while ZYBT trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas ZYBT's P/E ratio is -7.55. In terms of profitability, ETON's ROE is +1.05%, compared to ZYBT's ROE of -0.31%. Regarding short-term risk, ETON is more volatile compared to ZYBT. This indicates higher risk in terms of short-term price fluctuations for ETON.Check ZYBT's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
ETON vs ZYNE Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, ETON's ROE is +1.05%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, ETON is more volatile compared to ZYNE. This indicates higher risk in terms of short-term price fluctuations for ETON.Check ZYNE's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
ETON vs SSIC Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas SSIC's P/E ratio is 11.93. In terms of profitability, ETON's ROE is +1.05%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, ETON is more volatile compared to SSIC. This indicates higher risk in terms of short-term price fluctuations for ETON.Check SSIC's competition here
The Valens Company Inc. (NASDAQ: VLNS)
ETON vs VLNS Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas VLNS's P/E ratio is -1.03. In terms of profitability, ETON's ROE is +1.05%, compared to VLNS's ROE of N/A. Regarding short-term risk, ETON is more volatile compared to VLNS. This indicates higher risk in terms of short-term price fluctuations for ETON.Check VLNS's competition here
DURECT Corporation (NASDAQ: DRRX)
ETON vs DRRX Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas DRRX's P/E ratio is -4.44. In terms of profitability, ETON's ROE is +1.05%, compared to DRRX's ROE of -0.70%. Regarding short-term risk, ETON is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for ETON.Check DRRX's competition here
Talphera, Inc. (NASDAQ: TLPH)
ETON vs TLPH Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, TLPH has a market cap of 54.5M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while TLPH trades at $1.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas TLPH's P/E ratio is -3.89. In terms of profitability, ETON's ROE is +1.05%, compared to TLPH's ROE of -0.87%. Regarding short-term risk, ETON is more volatile compared to TLPH. This indicates higher risk in terms of short-term price fluctuations for ETON.Check TLPH's competition here
InterCure Ltd. (NASDAQ: INCR)
ETON vs INCR Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, INCR has a market cap of 51.2M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while INCR trades at $3.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas INCR's P/E ratio is -4.16. In terms of profitability, ETON's ROE is +1.05%, compared to INCR's ROE of -0.09%. Regarding short-term risk, ETON is more volatile compared to INCR. This indicates higher risk in terms of short-term price fluctuations for ETON.Check INCR's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
ETON vs JUPW Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas JUPW's P/E ratio is -2.41. In terms of profitability, ETON's ROE is +1.05%, compared to JUPW's ROE of -3.04%. Regarding short-term risk, ETON is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for ETON.Check JUPW's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
ETON vs QLI Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas QLI's P/E ratio is -4.92. In terms of profitability, ETON's ROE is +1.05%, compared to QLI's ROE of -0.16%. Regarding short-term risk, ETON is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for ETON.Check QLI's competition here
HEXO Corp. (NASDAQ: HEXO)
ETON vs HEXO Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas HEXO's P/E ratio is -0.26. In terms of profitability, ETON's ROE is +1.05%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, ETON is more volatile compared to HEXO. This indicates higher risk in terms of short-term price fluctuations for ETON.Check HEXO's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
ETON vs RMTI Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, RMTI has a market cap of 28.5M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while RMTI trades at $7.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas RMTI's P/E ratio is -5.28. In terms of profitability, ETON's ROE is +1.05%, compared to RMTI's ROE of -0.14%. Regarding short-term risk, ETON is more volatile compared to RMTI. This indicates higher risk in terms of short-term price fluctuations for ETON.Check RMTI's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
ETON vs SHPH Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, SHPH has a market cap of 25M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while SHPH trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas SHPH's P/E ratio is -0.24. In terms of profitability, ETON's ROE is +1.05%, compared to SHPH's ROE of -1.57%. Regarding short-term risk, ETON is more volatile compared to SHPH. This indicates higher risk in terms of short-term price fluctuations for ETON.Check SHPH's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
ETON vs CYTH Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas CYTH's P/E ratio is -0.80. In terms of profitability, ETON's ROE is +1.05%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, ETON is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for ETON.Check CYTH's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
ETON vs CPHI Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, CPHI has a market cap of 22.7M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while CPHI trades at $0.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas CPHI's P/E ratio is -1.23. In terms of profitability, ETON's ROE is +1.05%, compared to CPHI's ROE of -0.17%. Regarding short-term risk, ETON is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for ETON.Check CPHI's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
ETON vs TXMD Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, TXMD has a market cap of 20.8M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while TXMD trades at $1.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas TXMD's P/E ratio is 91.70. In terms of profitability, ETON's ROE is +1.05%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, ETON is more volatile compared to TXMD. This indicates higher risk in terms of short-term price fluctuations for ETON.Check TXMD's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
ETON vs AYTU Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, AYTU has a market cap of 20M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while AYTU trades at $1.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas AYTU's P/E ratio is -1.56. In terms of profitability, ETON's ROE is +1.05%, compared to AYTU's ROE of -0.53%. Regarding short-term risk, ETON is more volatile compared to AYTU. This indicates higher risk in terms of short-term price fluctuations for ETON.Check AYTU's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
ETON vs EVOK Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas EVOK's P/E ratio is -7.97. In terms of profitability, ETON's ROE is +1.05%, compared to EVOK's ROE of -0.70%. Regarding short-term risk, ETON is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for ETON.Check EVOK's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
ETON vs ACRX Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas ACRX's P/E ratio is -0.31. In terms of profitability, ETON's ROE is +1.05%, compared to ACRX's ROE of -0.87%. Regarding short-term risk, ETON is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for ETON.Check ACRX's competition here
Optimi Health Corp. (NASDAQ: OPTH)
ETON vs OPTH Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, OPTH has a market cap of 13.7M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while OPTH trades at $2.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas OPTH's P/E ratio is -1.54. In terms of profitability, ETON's ROE is +1.05%, compared to OPTH's ROE of -0.90%. Regarding short-term risk, ETON is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for ETON.Check OPTH's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
ETON vs AGRX Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas AGRX's P/E ratio is -0.89. In terms of profitability, ETON's ROE is +1.05%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, ETON is more volatile compared to AGRX. This indicates higher risk in terms of short-term price fluctuations for ETON.Check AGRX's competition here
Caring Brands, Inc. (NASDAQ: CABR)
ETON vs CABR Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, CABR has a market cap of 8.6M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while CABR trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas CABR's P/E ratio is -1.21. In terms of profitability, ETON's ROE is +1.05%, compared to CABR's ROE of -3.86%. Regarding short-term risk, ETON is less volatile compared to CABR. This indicates lower risk in terms of short-term price fluctuations for ETON.Check CABR's competition here
InMed Pharmaceuticals Inc. (NASDAQ: INM)
ETON vs INM Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, INM has a market cap of 8.5M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while INM trades at $15.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas INM's P/E ratio is -5.07. In terms of profitability, ETON's ROE is +1.05%, compared to INM's ROE of -3.04%. Regarding short-term risk, ETON is less volatile compared to INM. This indicates lower risk in terms of short-term price fluctuations for ETON.Check INM's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
ETON vs NLTX Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas NLTX's P/E ratio is -0.28. In terms of profitability, ETON's ROE is +1.05%, compared to NLTX's ROE of -0.44%. Regarding short-term risk, ETON is more volatile compared to NLTX. This indicates higher risk in terms of short-term price fluctuations for ETON.Check NLTX's competition here
Lannett Company, Inc. (NYSE: LCI)
ETON vs LCI Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas LCI's P/E ratio is -0.04. In terms of profitability, ETON's ROE is +1.05%, compared to LCI's ROE of +1.66%. Regarding short-term risk, ETON is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for ETON.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
ETON vs ADMP Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas ADMP's P/E ratio is -0.08. In terms of profitability, ETON's ROE is +1.05%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, ETON is more volatile compared to ADMP. This indicates higher risk in terms of short-term price fluctuations for ETON.Check ADMP's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
ETON vs SNOA Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, SNOA has a market cap of 5.9M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while SNOA trades at $1.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas SNOA's P/E ratio is -1.12. In terms of profitability, ETON's ROE is +1.05%, compared to SNOA's ROE of -0.36%. Regarding short-term risk, ETON is less volatile compared to SNOA. This indicates lower risk in terms of short-term price fluctuations for ETON.Check SNOA's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFM)
ETON vs SBFM Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, SBFM has a market cap of 5.8M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while SBFM trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas SBFM's P/E ratio is -0.45. In terms of profitability, ETON's ROE is +1.05%, compared to SBFM's ROE of -0.24%. Regarding short-term risk, ETON is more volatile compared to SBFM. This indicates higher risk in terms of short-term price fluctuations for ETON.Check SBFM's competition here
Mallinckrodt plc (AMEX: MNK)
ETON vs MNK Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas MNK's P/E ratio is -0.44. In terms of profitability, ETON's ROE is +1.05%, compared to MNK's ROE of -0.33%. Regarding short-term risk, ETON is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for ETON.Check MNK's competition here
cbdMD, Inc. (AMEX: YCBD)
ETON vs YCBD Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, YCBD has a market cap of 4.4M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while YCBD trades at $0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas YCBD's P/E ratio is -0.97. In terms of profitability, ETON's ROE is +1.05%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, ETON is more volatile compared to YCBD. This indicates higher risk in terms of short-term price fluctuations for ETON.Check YCBD's competition here
Flora Growth Corp. (NASDAQ: FLGC)
ETON vs FLGC Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas FLGC's P/E ratio is -0.19. In terms of profitability, ETON's ROE is +1.05%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, ETON is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for ETON.Check FLGC's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFMW)
ETON vs SBFMW Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, SBFMW has a market cap of 4.2M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while SBFMW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas SBFMW's P/E ratio is N/A. In terms of profitability, ETON's ROE is +1.05%, compared to SBFMW's ROE of -0.24%. Regarding short-term risk, ETON is more volatile compared to SBFMW. This indicates higher risk in terms of short-term price fluctuations for ETON.Check SBFMW's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
ETON vs GELS Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, GELS has a market cap of 3.9M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while GELS trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas GELS's P/E ratio is -0.96. In terms of profitability, ETON's ROE is +1.05%, compared to GELS's ROE of -0.36%. Regarding short-term risk, ETON is more volatile compared to GELS. This indicates higher risk in terms of short-term price fluctuations for ETON.Check GELS's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
ETON vs PLXP Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas PLXP's P/E ratio is -0.22. In terms of profitability, ETON's ROE is +1.05%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, ETON is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for ETON.Check PLXP's competition here
Athenex, Inc. (NASDAQ: ATNX)
ETON vs ATNX Comparison November 2026
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETON stands at 2B. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, ETON is priced at $68.40 on the NASDAQ, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETON currently has a P/E ratio of 180.00, whereas ATNX's P/E ratio is -0.02. In terms of profitability, ETON's ROE is +1.05%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, ETON is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for ETON.Check ATNX's competition here